New data presented 12-16 September at the MDS 2020 Virtual Congress further support the efficacy and tolerability of ONGENTYS® (opicapone) observed in pivotal Phase III studies. Opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor, approved for the treatment of end-of-dose motor fluctuations in adult PD patients taking levodopa. Data from OPTIPARK study demonstrated consistently low incidence of treatment-related adverse events in clinical practice from the…
Category: parkinson’s disease
Topline results of Phase 1-2 CDNF trial
Industry news from Herantis Pharma
MasterClass on the non-oral therapies and new NICE guideline for Parkinson’s
With publication of the new NICE guideline for Parkinson’s, Parkinson’s Academy is holding a series of roadshows exploring the non-oral therapy pathway in detail
In Parkinson’s disease, patients may suffer from delayed ON as well as wearing OFF – which is more important?
Report from Britannia Pharmaceuticals on their plenary session on PD treatment, held at the 9th CONy Congress in Budapest, Hungary, March 2015
